Navigation

Appraisals in development

This table lists NICE technology appraisals. The list can be sorted by title (alphabetically), wave number, anticipated publication date and process. You can also click the appraisal title for full details, or click a column heading to sort the list by that column.

Appraisals in development

Results 1-20 of 152

Title Anticipated publication date Referral date Process
Acute coronary syndrome - prasugrel with PCI (review TA182) [ID 648] Aug 2014 MTA
Acute coronary syndrome - rivaroxaban [ID532] Mar 2015 May 2012 STA
Alcohol dependence - nalmefene [ID660] Nov 2014 Oct 2013 STA
Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin) (inc rev TA142) [ID541] Aug 2014 MTA
Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) - adalimumab, etanercept infliximab and golimumab (inc rev TA143 and TA233) Jan 2015 MTA
Arrythmias - ICDs & Heart failure - cardiac resynchronisation [ID481] Jun 2014 MTA
Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95] TBC Jul 2009 STA
Atrial fibrillation - idraparinux sodium [ID375] TBC Nov 2005 STA
Atrial fibrillation - vernakalant [ID454] TBC May 2011 STA
Atrial fibrillation - ximelagatran [ID376] TBC Oct 2000 MTA
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83] TBC Apr 2009 STA
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405] TBC Nov 2011 STA
Bradycardia - dual chamber pacemakers (review of TA88) [ID697] Feb 2015 MTA
Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319] TBC Mar 2009 STA
Breast cancer (advanced or metastatic) - lapatinib [ID20] TBC Dec 2006 STA
Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115] TBC Dec 2007 STA
Breast cancer (early) - intrabeam radiotherapy system [ID618] Nov 2014 MTA
Breast cancer (ErbB2 HER2, metastatic) - lapatinib (with paclitaxel, 1st line) [ID517] TBC Nov 2011 STA
Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58] TBC Mar 2009 STA
Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488] TBC Nov 2011 STA

This page was last updated: 17 April 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.